Literature DB >> 10234569

Characterization of mouse cathepsin K gene, the gene promoter, and the gene expression.

Y P Li1, W Chen.   

Abstract

Cathepsin K, a lysosomal cysteine protease, is abundantly and selectively expressed in osteoclasts and has a specialized role in osteoclast-mediated bone resorption. In contrast to function studies, transcription regulation of cathepsin K remains largely unknown. In this study, the gene encoding mouse cathepsin K and the promoter have been isolated and completely sequenced. In addition, the temporal and spatial expressions of cathepsin K have been characterized. Intrachromosomal mapping studies revealed that the gene contains eight exons and seven introns spanning approximately 10.6 kb of genomic DNA, a genomic organization that was highly conserved with respect to its human homology. Analysis of the 9 kb 5' flanking region indicates that this gene lacks canonical TATA and CAAT boxes and contains multiple putative transcription regulatory elements which are also present in the comparable position of 5' flanking region of human cathepsin K gene. Mouse cathepsin K was found to be a single-copy gene. Northern blot analysis of RNAs from a number of mouse tissues revealed that cathepsin K mRNA is selectively expressed in osteoclast. The selective expression of cathepsin K was confirmed by anticathepsin K immunohistochemical staining. The sequence of cathepsin K expression was linked to osteoclast differentiation in vivo and in vitro by a tartrate-resistant acid phosphatase-anticathepsin K dual immunostaining technique. Cathepsin K is initially expressed at the preosteoclast stage and throughout the mature osteoclast stage. The primer extension assay indicated a major transcription start site 58 bp upstream of the initiator Met codon. The characterization of the cathepsin K gene, its promoter, and the temporal and spatial expression may provide valuable insights into its osteoclast-specific expression and the molecular mechanisms responsible for osteoclast activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10234569     DOI: 10.1359/jbmr.1999.14.4.487

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  16 in total

1.  The silencing of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection and inflammation.

Authors:  W Chen; B Gao; L Hao; G Zhu; J Jules; M J MacDougall; J Wang; X Han; X Zhou; Y-P Li
Journal:  J Periodontal Res       Date:  2016-01-11       Impact factor: 4.419

2.  Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.

Authors:  Liang Hao; Jianwei Chen; Zheng Zhu; Michael S Reddy; John D Mountz; Wei Chen; Yi-Ping Li
Journal:  J Periodontol       Date:  2015-04-16       Impact factor: 6.993

3.  Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells.

Authors:  Debomoy K Lahiri; Bryan Maloney; Yuan-Wen Ge
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 4.  Signaling networks that control the lineage commitment and differentiation of bone cells.

Authors:  Carrie S Soltanoff; Shuying Yang; Wei Chen; Yi-Ping Li
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

5.  Inhibition of the classical NF-kappaB pathway prevents osteoclast bone-resorbing activity.

Authors:  Niroshani S Soysa; Neil Alles; Hitoyata Shimokawa; Eijiro Jimi; Kazuhiro Aoki; Keiichi Ohya
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

6.  A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.

Authors:  Liang Hao; Wei Chen; Matthew McConnell; Zheng Zhu; Sheng Li; Michael Reddy; Paul D Eleazer; Min Wang; Yi-Ping Li
Journal:  Infect Immun       Date:  2015-01-12       Impact factor: 3.441

7.  Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role.

Authors:  Liang Hao; Guochun Zhu; Yun Lu; Min Wang; Joel Jules; Xuedong Zhou; Wei Chen
Journal:  FEBS Lett       Date:  2015-04-17       Impact factor: 4.124

8.  Pulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis.

Authors:  Anna Cline-Smith; Jesse Gibbs; Elena Shashkova; Zachary S Buchwald; Deborah V Novack; Rajeev Aurora
Journal:  JCI Insight       Date:  2016-08-18

9.  IL-1alpha stimulates cathepsin K expression in osteoclasts via the tyrosine kinase-NF-kappaB pathway.

Authors:  S Kamolmatyakul; W Chen; S Yang; Y Abe; R Moroi; A M Ashique; Y-P Li
Journal:  J Dent Res       Date:  2004-10       Impact factor: 6.116

Review 10.  Applications of transgenics in studies of bone sialoprotein.

Authors:  Jin Zhang; Qisheng Tu; Jake Chen
Journal:  J Cell Physiol       Date:  2009-07       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.